Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$25.91+1.00 (+4.01%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield –
Alto Neuroscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Alto Neuroscience's operating income for the twelve months ending Sep 30, 2026 was -$100.55M. For fiscal 2025 it was -$66.36M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$66.36M | – |
| FY2024 | Dec 31, 2024 | -$68.61M | – |
| FY2023 | Dec 31, 2023 | -$37.81M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$27.23M | – |
| Q2 FY2026 | Jun 30, 2026 | -$29.13M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$18.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.20M | – |
See a number that looks wrong?